Kinase Inhibitor Discovery
with an untiring quest for future therapeutics

Carna Opens Dose Expansion Part of Phase 1b Study for Next Generation BTK Inhibitor AS-1763

FY2024 Q2 Presentation

Consolidated Financial Results for the Second Quarter of the Year Ending December 31, 2024

AS-1763, a next generation BTK inhibitor, demonstrates encouraging safety and efficacy in patients with B-cell malignancies in Phase 1b study

Carna announces acceptance of a poster on AS-1763 for presentation at European Hematology Association (EHA) 2024

FY2024 Q1 Presentation

Consolidated Financial Results for the First Quarter of the Year Ending December 31, 2024

Carna presented a poster on monzosertib at AACR Annual Meeting